samedan logo
 
 
 
spacer
home > ebr > summer 2003 > the future of vaccines
PUBLICATIONS
European Biopharmaceutical Review

The Future of Vaccines

Estimated at about $6 billion annually, the current worldwide market for vaccines centres around a list of old enemies such as tuberculosis, typhoid, cholera, tetanus, diphtheria, rabies, smallpox, yellow fever and polio. Newer vaccines have been created for chickenpox, Hepatitis B and A, influenza and pneumonia. Today, with the power of genomics, proteomics and systems biology at our fingertips, we've entered into what many believe will be a golden age for prophylactic approaches. Enter the era of 'super vaccines' -vaccines that will mitigate everything from herpes, to cancers and even AIDS. Some of them will be tailor-made to fit the individual's genetic profile.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By G Steven Burrill, CEO of Burrill & Company

G Steven Burrill is CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. Mr Burrill currently serves on eight Boards of Directors including DepoMed (Amex: DMI) and Third Wave Technologies (NASDAQ: TWTI), and is Chairman of the Boards of Pyxis Genomics and Paradigm Genetics (NASDAQ: PDGM).

Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young directing and co-ordinating the firm's services to clients in the biotechnology, life sciences, high technology and manufacturing industries worldwide.

spacer
G Steven Burrill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera wins Pharmapack Award in Connected Devices and Wearables category with its body injector platform Symbioze

Symbioze, the smart, high volume and sustainable on-body injector platform developed by Nemera, wins the ‘Connected Devices and Wearables’ Award at Pharmapack 2021 On October 12th, during the Pharmapack Awards Ceremony, a team of industry experts awarded Symbioze, Nemera’s large-volume on-body injector, with the Pharmapack Award in the “Connected Devices and Wearables” category.
More info >>

White Papers

Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products

Entegris

The pharmaceutical industry is migrating rapidly toward a world where drugs, vaccines, and specialized therapies are available on demand to patients anywhere around the globe. Whether accelerating clinical trials to bring new drugs to market or devel oping biosimilars to give more patients access to established commercial drugs, small and midsize production facilities stand to benefit from growing demand. To do so, however, they must be prepared to handle a broader mix of products and increase throughput without sacrificing safety or reliability, while at the same time keeping life-saving medica tions affordable. Such challenges become more difficult when working with products that must be stored and shipped in a frozen state.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement